Restoration of Meibomian Gland Functionality with Novel Mesenchymal Stem Cell-Derived Product “Derived-Multiple Allogeneic Proteins Paracrine Signaling (d-MAPPS)”: A Case Report

1 Butovich IA. Meibomian glands, meibum, and meibogenesis. Exp Eye Res. 2017;163:2-16. Search in Google Scholar

2 Arita R, Fukuoka S, Morishige N. New insights into the morphology and function of meibomian glands. Exp Eye Res. 2017;163:64-71. Search in Google Scholar

3 Arita R, Fukuoka S, Morishige N. New Insights Into the Lipid Layer of the Tear Film and Meibomian Glands. Eye Contact Lens. 2017;43:335-339. Search in Google Scholar

4 Foulks GN, Borchman D. Meibomian gland dysfunction: the past, present, and future. Eye Contact Lens. 2010;36:249-253. Search in Google Scholar

5 Hwang HS, Parfitt GJ, Brown DJ, Jester JV. Meibocyte differentiation and renewal: Insights into novel mechanisms of meibomian gland dysfunction (MGD). Exp Eye Res. 2017;163:37-45. Search in Google Scholar

6 Jester JV, Parfitt GJ, Brown DJ. Meibomian gland dysfunction: hyperkeratinization or atrophy? BMC Ophthalmol. 2015;15 Suppl 1:156. Search in Google Scholar

7 Jester JV, Potma E, Brown DJ. PPARγ Regulates Mouse Meibocyte Differentiation and Lipid Synthesis. Ocul Surf. 2016;14:484-494. Search in Google Scholar

8 Xie HT, Sullivan DA, Chen D, Hatton MP, Kam WR, Liu Y. Biomarkers for Progenitor and Differentiated Epithelial Cells in the Human Meibomian Gland. Stem Cells Transl Med. 2018;7:887-892. Search in Google Scholar

9 Paranjpe V, Tan J, Nguyen J, Lee J, Allegood J, Galor A, et al. Clinical signs of meibomian gland dysfunction (MGD) are associated with changes in meibum sphingolipid composition. Ocul Surf. 2019;17:318-326. Search in Google Scholar

10 Sabeti S, Kheirkhah A, Yin J, Dana R. Management of meibomian gland dysfunction: a review. Surv Ophthalmol. 2020;65:205-217. Search in Google Scholar

11 Villatoro AJ, Fernández V, Claros S, Alcoholado C, Cifuentes M, Merayo-Lloves J, et al. Regenerative Therapies in Dry Eye Disease: From Growth Factors to Cell Therapy. Int J Mol Sci. 2017;18(11). Search in Google Scholar

12 Volarevic V, Gazdic M, Simovic Markovic B, Jovicic N, Djonov V, Arsenijevic N. Mesenchymal stem cell-derived factors: Immuno-modulatory effects and therapeutic potential. Biofactors. 2017;43:633-644. Search in Google Scholar

13 Harrell CR, Fellabaum C, Simovic Markovic B, Arsenijevic A, Volarevic V. Therapeutic potential of “Exosomes derived Multiple Allogeneic Proteins Paracrine Signaling: Exosomes d-MAPPS” is based on the effects of exosomes, immunosuppressive and trophic factors. Ser J of Exp Clin Res. 2019;20:189-197. Search in Google Scholar

14 Harrell CR, Fellabaum C, Simovic Markovic B, Miloradovic D, Acovic A, Miloradovic D, et al. Exo-d-MAPPS attenuates production of inflammatory cytokines and promotes production of inflammatory cytokines in peripheral blood mononuclear cells. Ser J Exp Clin Res 2020; doi:10.2478/sjecr-2019-0045. Search in Google Scholar

15 Harrell CR, Simovic Markovic B, Fellabaum C, Arsenijevic A, Djonov V, Arsenijevic N, et al. Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Eye Diseases. Adv Exp Med Biol. 2018;1089:47-57. Search in Google Scholar

16 Ji YW, Lee J, Lee H, Seo KY, Kim EK, Kim TI. Automated Measurement of Tear Film Dynamics and Lipid Layer Thickness for Assessment of Non-Sjögren Dry Eye Syndrome With Meibomian Gland Dysfunction. Cornea. 2017;36:176-182. Search in Google Scholar

17 Beyazyıldız E, Pınarlı FA, Beyazyıldız O, Hekimoğlu ER, Acar U, Demir MN, et al. Efficacy of topical mesenchymal stem cell therapy in the treatment of experimental dry eye syndrome model. Stem Cells Int. 2014;2014:250230. Search in Google Scholar

18 Gazdic M, Volarevic V, Arsenijevic N, Stojkovic M. Mesenchymal stem cells: a friend or foe in immune-mediated diseases. Stem Cell Rev Rep. 2015;11:280-287. Search in Google Scholar

19 Aluri HS, Samizadeh M, Edman MC, Hawley DR, Armaos HL, Janga SR, et al. Delivery of Bone Marrow- Derived Mesenchymal Stem Cells Improves Tear Production in a Mouse Model of Sjögren’s Syndrome. Stem Cells Int. 2017;2017:3134543. Search in Google Scholar

20 Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential risks of bone marrow cell transplantation into infarcted hearts. Blood. 2007;110:1362-1369. Search in Google Scholar

21 Yoon YS, Park JS, Tkebuchava T, Luedeman C, Losordo DW. Unexpected severe calcification after transplantation of bone marrow cells in acute myocardial infarction. Circulation. 2004;109:3154-157. Search in Google Scholar

22 Berglund AK, Schnabel LV. Allogeneic major histocompatibility complex-mismatched equine bone marrow- derived mesenchymal stem cells are targeted for death by cytotoxic anti-major histocompatibility complex antibodies. Equine Vet J. 2017;49:539-544. Search in Google Scholar

23 Berglund AK, Fortier LA, Antczak DF, Schnabel LV. Immunoprivileged no more: measuring the immunogenicity of allogeneic adult mesenchymal stem cells. Stem Cell Res Ther. 2017;8:288. Search in Google Scholar

24 Pezzanite LM, Fortier LA, Antczak DF, Cassano JM, Brosnahan MM, Miller D, et al. Equine allogeneic bone marrow-derived mesenchymal stromal cells elicit antibody responses in vivo. Stem Cell Res Ther. 2015;6:54. Search in Google Scholar

25 Griffin MD, Ryan AE, Alagesan S, Lohan P, Treacy O, Ritter T. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? Immunol Cell Biol. 2013;91:40-51. Search in Google Scholar

26 Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. Ethical and Safety Issues of Stem Cell-Based Therapy. Int J Med Sci. 2018;15:36-45. Search in Google Scholar

27 Choi W, Noh H, Yeo A, Jang H, Ahn HK, Song YJ, et al. The Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye Inflammation. Korean J Ophthalmol. 2016;30:302-308. Search in Google Scholar

28 Yucekul B, Mocan MC, Kocabeyoglu S, Tan C, Irkec M. Evaluation of Long-Term Silicone Hydrogel Use on Ocular Surface Inflammation and Tear Function in Patients With and Without Meibomian Gland Dysfunction. Eye Contact Lens. 2019;45:61-66. Search in Google Scholar

29 Fabiani C, Sota J, Tosi GM, Franceschini R, Frediani B, Galeazzi M, et al. The emerging role of interleukin (IL)- 1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clin Rheumatol. 2017;36:2307-2318. Search in Google Scholar

30 Choi M, Han SJ, Ji YW, Choi YJ, Jun I, Alotaibi MH, et al. Meibum Expressibility Improvement as a Therapeutic Target of Intense Pulsed Light Treatment in Meibomian Gland Dysfunction and Its Association with Tear Inflammatory Cytokines. Sci Rep. 2019;9:7648. Search in Google Scholar

31 Sakimoto T, Ohnishi T, Ishimori A. Significance of ectodomain shedding of TNF receptor 1 in ocular surface. Invest Ophthalmol Vis Sci. 2014;55:2419-2423. Search in Google Scholar

32 Harrell CR, Markovic BS, Fellabaum C, Arsenijevic N, Djonov V, Volarevic V. The role of Interleukin 1 receptor antagonist in mesenchymal stem cell-based tissue repair and regeneration. Biofactors. 2019 Nov 22. doi: 10.1002/biof.1587. Search in Google Scholar

33 Kovalchin J, King B, Masci A, Hopkins E, Fry J, Hou J, et al. Preclinical Development of EBI-005: An IL-1 Receptor- 1 Inhibitor for the Topical Ocular Treatment of Ocular Surface Inflammatory Diseases. Eye Contact Lens. 2018;44:170-181. Search in Google Scholar